Ricardo L M Duarte1,2, Marcelo F Rabahi3, Tiago S Oliveira-E-Sá4,5, Flavio J Magalhães-da-Silveira6, Fernanda C Q Mello7, David Gozal8. 1. Sleep - Laboratório de Estudo dos Distúrbios do Sono, Centro Médico BarraShopping, Avenida das Américas 4666, sala 309, Barra da Tijuca, Rio de Janeiro, 22649-900, Brazil. rlmduarte@gmail.com. 2. Instituto de Doenças do Tórax - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. rlmduarte@gmail.com. 3. Faculdade de Medicina, Universidade Federal de Goiás, Goiânia, Goiás, Brazil. 4. Hospital de Santa Marta - Centro Hospitalar Lisboa Central, Lisbon, Portugal. 5. NOVA Medical School - Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal. 6. Sleep - Laboratório de Estudo dos Distúrbios do Sono, Centro Médico BarraShopping, Avenida das Américas 4666, sala 309, Barra da Tijuca, Rio de Janeiro, 22649-900, Brazil. 7. Instituto de Doenças do Tórax - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. 8. Department of Child Health, University of Missouri School of Medicine, Columbia, MO, USA.
Abstract
PURPOSE: Obstructive sleep apnea (OSA) is a common condition characterized by repetitive collapse of the upper airways and intermittent oxygen desaturation, which may lead to airway inflammation. Here, we explored whether fractional exhaled nitric oxide (FeNO) levels provide a non-invasive screening tool of OSA. METHODS: Over a 3-month period, FeNO levels were measured in consecutive non-smoking patients referred for a sleep laboratory. All patients underwent full polysomnography. OSA severity was classified based on the apnea/hypopnea index: ≥ 5.0/h as any OSA, ≥ 15.0/h as moderate/severe OSA, and ≥ 30.0/h as severe OSA. FeNO was measured by a portable device (NIOX-MINO®; Aerocrine AB, Solna, Sweden) and expressed as parts per billion (ppb). Discrimination by area under the curve (AUC) and binary logistic regression were performed. RESULTS: A total of 229 subjects were evaluated. Mean FeNO values were similar among subjects without OSA or with OSA: 16.9 ± 10.6 ppb versus 20.2 ± 14.5 ppb, p = 0.221; respectively. FeNO was not an inclusionary parameter to predict any OSA, moderate/severe OSA, and severe OSA: odds ratio (OR) 1.023 (95% confidence interval [CI]: 0.986-1.062); OR 1.012 (95% CI: 0.991-1.034); and OR 0.999 (95% CI: 0.980-1.018), respectively. The AUC values for FeNO in the diagnosis of any OSA, moderate/severe OSA, and severe OSA showed no discriminatory properties: AUC: 0.567 (95% CI: 0.464-0.670), AUC: 0.541 (95% CI: 0.465-0.618), and AUC: 0.535 (95% CI: 0.459-0.610); respectively. CONCLUSIONS: In a sleep-lab setting, our findings suggest that FeNO measurements are inconsequential in the screening of OSA in adults.
PURPOSE: Obstructive sleep apnea (OSA) is a common condition characterized by repetitive collapse of the upper airways and intermittent oxygen desaturation, which may lead to airway inflammation. Here, we explored whether fractional exhaled nitric oxide (FeNO) levels provide a non-invasive screening tool of OSA. METHODS: Over a 3-month period, FeNO levels were measured in consecutive non-smoking patients referred for a sleep laboratory. All patients underwent full polysomnography. OSA severity was classified based on the apnea/hypopnea index: ≥ 5.0/h as any OSA, ≥ 15.0/h as moderate/severe OSA, and ≥ 30.0/h as severe OSA. FeNO was measured by a portable device (NIOX-MINO®; Aerocrine AB, Solna, Sweden) and expressed as parts per billion (ppb). Discrimination by area under the curve (AUC) and binary logistic regression were performed. RESULTS: A total of 229 subjects were evaluated. Mean FeNO values were similar among subjects without OSA or with OSA: 16.9 ± 10.6 ppb versus 20.2 ± 14.5 ppb, p = 0.221; respectively. FeNO was not an inclusionary parameter to predict any OSA, moderate/severe OSA, and severe OSA: odds ratio (OR) 1.023 (95% confidence interval [CI]: 0.986-1.062); OR 1.012 (95% CI: 0.991-1.034); and OR 0.999 (95% CI: 0.980-1.018), respectively. The AUC values for FeNO in the diagnosis of any OSA, moderate/severe OSA, and severe OSA showed no discriminatory properties: AUC: 0.567 (95% CI: 0.464-0.670), AUC: 0.541 (95% CI: 0.465-0.618), and AUC: 0.535 (95% CI: 0.459-0.610); respectively. CONCLUSIONS: In a sleep-lab setting, our findings suggest that FeNO measurements are inconsequential in the screening of OSA in adults.
Authors: Miguel-Angel Martínez-García; Francisco Capote; Francisco Campos-Rodríguez; Patricia Lloberes; María Josefa Díaz de Atauri; María Somoza; Juan F Masa; Mónica González; Lirios Sacristán; Ferrán Barbé; Joaquín Durán-Cantolla; Felipe Aizpuru; Eva Mañas; Bienvenido Barreiro; Mar Mosteiro; Juan J Cebrián; Mónica de la Peña; Francisco García-Río; Andrés Maimó; Jordi Zapater; Concepción Hernández; Nuria Grau SanMarti; Josep María Montserrat Journal: JAMA Date: 2013-12-11 Impact factor: 56.272
Authors: Richard B Berry; Rohit Budhiraja; Daniel J Gottlieb; David Gozal; Conrad Iber; Vishesh K Kapur; Carole L Marcus; Reena Mehra; Sairam Parthasarathy; Stuart F Quan; Susan Redline; Kingman P Strohl; Sally L Davidson Ward; Michelle M Tangredi Journal: J Clin Sleep Med Date: 2012-10-15 Impact factor: 4.062
Authors: Ai-Ping Chua; Loutfi S Aboussouan; Omar A Minai; Kelly Paschke; Daniel Laskowski; Raed A Dweik Journal: J Clin Sleep Med Date: 2013-06-15 Impact factor: 4.062
Authors: A Depalo; G E Carpagnano; A Spanevello; R Sabato; M G Cagnazzo; C Gramiccioni; M P Foschino-Barbaro Journal: J Intern Med Date: 2008-01 Impact factor: 8.989
Authors: Giovanna E Carpagnano; Antonio Spanevello; Roberto Sabato; Annarita Depalo; Viviana Turchiarelli; Maria Pia Foschino Barbaro Journal: Transl Res Date: 2007-10-11 Impact factor: 7.012
Authors: Ricardo L M Duarte; Flavio J Magalhães-da-Silveira; Tiago S Oliveira-E-Sá; Marcelo F Rabahi; Fernanda C Q Mello; David Gozal Journal: Lung Date: 2019-05-10 Impact factor: 2.584